Drug Trial Radar · NCT07311564
A Study of LAD603 in Adults With Alopecia Areata
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Jun 23, 2027
Study completion Nov 21, 2027
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Conditions
- Alopecia Areata
Interventions
LAD603Drug
LAD603 administered subcutaneously.
PlaceboOther
LAD603 matching placebo administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in the Severity of Alopecia Tool (SALT) ScoreTime frame: Baseline, Week 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigator Site 1
Omaha, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.